Abstract
Some studies were done to compare EBUS-TBNA with other methods.
The diagnostic finding of the EBUS-TBNA probes and every other medical report of the patient was recorded. Malignancies were subdivided in NSCLC NOS, Adenoca, Squamous Cell Ca, Small Cell Ca, Malignancies other than the lung cancer and Maligancies NOS. The same localisation of the lung analysed with TBNA was examined with another method such as resection or biopsy in selected cases. With this data, the accordance between the sampling techniques was controlled. Of these 222 TBNA probes, from lymphnode stations 7, 10, 4 and 2 such as upper thoracal lesions, in 206 (93%) cases a diagnose (tumor or not-tumor) was made, in 16 (7%) cases no clear diagnosis could be made concerning the worse tissue quality. 128 (62%) probes were without tumorcells and 38% probes contained tumorcells. EBUS-TBNA samples were compared with the resected tissue or biopsy findings. In 17 of 128 of tumor-containing samples had a resection or biopsy, 82% had the same diagnosis, 6% another diagnosis and in 12% cases no diagnosis could be made on this material.
These 78 tumor-containing probes 31% were also checked by biopsy or resection. In 75%cases the same diagnosis was made on EBUS-TBNA and the method. In 8%cases the diagnosis could not be specified and was doubtful, in 13% cases the diagnosis was different and in 4% case the EBUS-TBNA was done twice with two different diagnosis.
EBUS-TBNA was proved clinical as safe technique and reliable in lung cancer staging and metastases detection. Histological subtyping of lung cancer is possible such as molecular-pathological analysis can also be done from resected tissue or biopsy material.
- © 2011 ERS
